Get the Stockscreener App
4.74
3.66%
-0.18
After Hours:
4.74
Zentalis Pharmaceuticals Inc stock is traded at $4.74, with a volume of 941.18K.
It is down -3.66% in the last 24 hours and down -2.27% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$4.92
Open:
$4.95
24h Volume:
941.18K
Relative Volume:
0.81
Market Cap:
$337.42M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-2.7276
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
+9.47%
1M Performance:
-2.27%
6M Performance:
+95.06%
1Y Performance:
+243.48%
1-Day Range:
$4.66
$4.99
1-Week Range:
$4.1313
$5.10
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.74 | 321.05M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals Market Sentiment - Benzinga España
Zentalis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ZNTL - TradingView
TradingKey - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence - TradingKey
Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055 - TradingKey
ZNTL Initiated Coverage by Rodman & Renshaw -- Price Target Anno - GuruFocus
Rodman & Renshaw initiates Zentalis stock with buy on drug potential - Investing.com Canada
Zentalis Pharmaceuticals Inc (ZNTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ManpowerGroup posts upbeat Q2 earnings, joins Docebo, Zentalis Pharmaceuticals and other big stocks moving higher on Friday - MSN
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Yahoo! Finance Canada
ZENTALIS PHARMACEUTICALS INC : MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8 - Bitget
What date does Zentalis Pharmaceuticals's (ZNTL) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
ZNTL Jumps As Mizuho Targets Upside On Cancer Drug - StocksToTrade
Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL) - The Globe and Mail
Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo
Mizuho Securities Initiates Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Announces Target Price $8 - Moomoo
Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin - Benzinga
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform By Investing.com - Investing.com South Africa
Mizuho initiates Zentalis Pharmaceuticals stock at Outperform - Investing.com
ZNTL Initiates Coverage On by Mizuho -- Rating Set to Outperform - GuruFocus
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech - Ad-hoc-news.de
Zentalis Pharmaceuticals (ZNTL) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance - ad-hoc-news.de
ZNTL Q1 2026 Earnings: Slightly Wider Loss Meets Modest Stock UptickEarnings Quality Score - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Zentalis Pharmaceuticals (ZNTL) Rallies 5.21% as Biotech Sector Finds FootingScalping Stock Signals - dars.gov.et
Zentalis Pharmaceuticals Surges 14%: Biotech Stock Breaks Above Key Support ZoneBearish Pattern Stocks - dars.gov.et
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2000 Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000E Index - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2500 Value Benchmark - marketscreener.com
ZNTL Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Remains in FocusCost Structure Review - DonanımHaber
Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL) - TradingView
Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView
Zentalis Pharmaceuticals Inc (ZNTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zentalis Pharmaceuticals (ZNTL) Edges Higher as Biotech Sector Sees Mixed SentimentDividend Arbitrage - dars.gov.et
ZNTL Should I Buy - Intellectia AI
Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan
RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan
Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan
Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan
Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):